• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis - Product Image

Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis

  • Published: November 2012
  • 41 pages
  • GlobalData

Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’s SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

Rituxan was co-developed and marketed in the US (under the brand name Rituxan) by Biogen Idec and Genentech (now a part of Roche). It is marketed outside of the US by Roche under the brand name MabThera. Rituxan was initially approved for the treatment of lymphoma and it was the first mAb to be approved for the treatment of cancer. In 2006, Rituxan was approved in the US and 5EU for the treatment of moderate to severe active RA in patients who do not adequately respond to one or more TNF READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
4 Disease Management
4.1 Overview
4.2 Diagnosis
4.3 Treatment
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Product Profile - Rituxan/MabThera (rituximab)
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast
7 Appendix
7.1 Abbreviations
7.2 Bibliography
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 Diagnosed Rheumatoid Arthritis Patients
7.4.2 Percent Drug-treated Patients
7.4.3 General Pricing Assumptions
7.4.4 Individual Drug Assumptions
7.5 Physicians and Specialists Included in this Study
7.6 Primary Research - Prescriber Survey
7.7 About the Authors
7.7.1 Analysts
7.7.2 Global Head of Healthcare
7.8 About Us
7.9 Contact Us
7.10 Disclaimer

1.1 List of Tables
Table 1: Symptoms of Rheumatoid Arthritis
Table 2: Treatment Guidelines for Rheumatoid Arthritis
Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market
Table 4: Treatment Guidelines for Rheumatoid Arthritis
Table 5: Product Profile - Rituxan
Table 6: Rituxan SWOT Analysis, 2012
Table 7: Global Sales Forecasts ($m) for Rituxan
Table 8: Physicians Surveyed, By Country

1.2 List of Figures
Figure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis
Figure 2: Rheumatoid Arthritis Biologic Drug Targets
Figure 3: Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria Point System
Figure 4: Severity of Rheumatoid Arthritis
Figure 5: Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations-

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos